Auvi Labs

Cover Block

PUBLIC

Item	Detail
Company Name	Auvi Labs
Tagline	Wearable ultrasound designed to detect vascular access failure for hemodialysis patients. [Auvi Labs]
Headquarters	Champaign, IL
Founded	2024 [PitchBook]
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+) [Prospeo]
Funding Label	Pre-seed
Total Disclosed	~$136,000 (estimated) [Illinois Medicine, 2024][SignalBase]

Links

PUBLIC

• Website: https://www.auvilabs.com/
• LinkedIn: https://www.linkedin.com/company/auvilabs
• YouTube: https://www.youtube.com/watch?v=fDuFXmx-7DY

Executive Summary

PUBLIC Auvi Labs is developing a wearable ultrasound patch to detect vascular access failure in hemodialysis patients, a clinically significant problem that currently lacks a continuous, non-invasive monitoring solution [Auvi Labs]. The company, spun out of the University of Illinois at Urbana-Champaign in 2024, aims to reduce the high rate of complications and hospitalizations associated with arteriovenous fistula (AVF) stenosis by enabling early intervention [Illinois Medicine, 2024]. Its product, Beacon, is designed as a patch-like sensor patients would use for ten minutes daily to collect auditory data and flag narrowing before a complete failure occurs [YouTube]. The founding team, led by CEO Rishab Veldur and COO Kevin Volkema, leverages university research roots, though detailed professional backgrounds prior to the venture are not publicly documented [Delta: HealthTech Innovators]. To date, the company has secured modest pre-seed capital, including a $35,000 award from the Cozad New Venture Challenge and a reported $101,000 seed round, positioning it for early prototyping and regulatory pathway development [Illinois Medicine, 2024] [SignalBase]. Over the next 12-18 months, key milestones will include advancing the hardware prototype, initiating clinical validation studies, and securing additional funding to navigate the FDA clearance process for a Class II medical device. Data Accuracy: YELLOW -- Core product claims are from primary sources, but funding details rely on a single unverified report and team backgrounds lack independent corroboration.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	Hardware
Geography	North America
Growth Profile	Venture Scale
Founding Team	Co-Founders (3+)
Funding	Pre-seed (total disclosed ~$136,000)

Company Overview

PUBLIC

Auvi Labs is a 2024 company, spun out of the University of Illinois at Urbana-Champaign to address a specific and costly problem in kidney care [Auvi Labs]. The founding story centers on the high failure rate of vascular access points for hemodialysis patients, a clinical challenge the founders identified during their time at the university [Illinois Medicine, 2024]. The company is headquartered in Champaign, Illinois, a location consistent with its academic origins [Crunchbase].

Key early milestones are anchored in the university's entrepreneurial ecosystem. The most clearly documented event is the company's participation in the 2024 Cozad New Venture Challenge, where it secured second place and a $35,000 investment for its wearable monitoring concept [Illinois Medicine, 2024]. This was followed by a reported $101,000 seed funding round, though details on the lead investor for this round are not available from primary sources [SignalBase].

Beyond these initial funding events, public milestones are sparse. The company's LinkedIn presence and a founder interview video indicate ongoing product development for a device named "Beacon," but no regulatory clearances, pilot study announcements, or commercial partnerships have been publicly disclosed [YouTube] [LinkedIn, 2026]. The legal entity is listed as Auvi Labs Inc. in business directories [BBB].

Data Accuracy: YELLOW -- Core details (founding year, university spin-out, Cozad award) are confirmed by a primary university source. Other funding and entity details rely on single, unverified third-party reports.

Product and Technology

MIXED Auvi Labs is developing a hardware-software system aimed at a specific, high-stakes clinical problem: the early detection of vascular access failure in hemodialysis patients. The company’s core product, named Beacon, is described as a non-invasive, patch-like wearable ultrasound sensor [Auvi Labs]. According to a university publication, the device continuously monitors arteriovenous fistulas (AVFs), the surgically created connections used for dialysis, collecting auditory information to detect narrowing [Illinois Medicine, 2024]. The intended use case is for patients to wear the patch for approximately ten minutes daily, providing a routine check that could alert clinicians to intervene before a complete failure occurs [YouTube].

The technology stack is inferred to combine custom ultrasound transducer hardware, signal processing algorithms for detecting flow anomalies, and a companion software platform for data visualization and clinician alerts. The public positioning emphasizes early detection and continuous monitoring, suggesting the system is designed for home use rather than exclusively in-clinic settings. No detailed specifications, such as battery life, connectivity method (e.g., Bluetooth), or sensor reuse parameters, are publicly available. The company has not released a public roadmap or announced specific regulatory milestones, such as FDA submission or clearance.

Data Accuracy: YELLOW -- Product claims are consistent across the company's website and a university press release, but technical specifications and development status are not detailed.

Market Research

PUBLIC The need for reliable, early-stage monitoring in chronic kidney disease is driven by a costly and growing patient population, where failure of vascular access is the primary cause of hospitalization. The market for Auvi Labs' proposed solution is defined by the intersection of the hemodialysis patient population, the clinical protocols for vascular access surveillance, and the nascent but expanding category of wearable point-of-care ultrasound devices.

Quantifying the total addressable market for a novel diagnostic device is challenging at this stage. Public third-party reports on the specific market for wearable ultrasound for dialysis access are not available in the cited sources. However, the scale of the underlying patient population provides a relevant analog. In the United States, over 800,000 people live with end-stage renal disease (ESRD), with the majority, approximately 560,000, receiving maintenance hemodialysis [National Institute of Diabetes and Digestive and Kidney Diseases]. Each of these patients relies on a functioning vascular access point, typically an arteriovenous fistula (AVF), which has a high failure rate. The annual cost of managing vascular access complications and hospitalizations for this cohort runs into the billions of dollars, establishing a clear economic incentive for any technology that can reduce these events.

Demand is anchored by a persistent clinical problem. Fistula stenosis, a narrowing of the blood vessel, is a leading cause of access failure, often requiring emergency surgical intervention. Current monitoring standards are intermittent and reactive, relying on physical examination during dialysis sessions or periodic ultrasound scans in a clinic. This creates a significant detection gap. The clinical tailwind is a growing emphasis on value-based care models in nephrology, which financially reward providers for preventing costly complications and improving patient outcomes. A wearable device that enables continuous, at-home monitoring aligns directly with this shift, offering a potential tool for proactive intervention.

Key adjacent markets include the broader remote patient monitoring (RPM) sector and the point-of-care ultrasound (POCUS) device market. The RPM market, valued in the tens of billions globally, is expanding rapidly, driven by reimbursement code expansions and post-pandemic adoption of telehealth [analogous market, Rock Health]. The miniaturization of ultrasound technology, moving from cart-based systems to handheld and now wearable form factors, represents a parallel technological trend. Auvi Labs' proposition sits at the convergence of these two larger, validated markets.

Regulatory and macro forces present both a hurdle and a potential catalyst. The device will require FDA clearance, a process that defines the timeline to any commercial launch. The macro environment for healthtech funding has become more selective, favoring companies with clear clinical utility and a path to reimbursement. Success will depend on demonstrating not just technical feasibility but also a compelling health economic argument to payers, likely focusing on reduction in hospitalizations and associated Medicare costs.

Data Accuracy: YELLOW -- Market sizing is inferred from analogous public health data and adjacent sector reports; specific TAM for the product category is not cited.

Competitive Landscape

MIXED Auvi Labs enters a medical device niche where competitive pressure is defined less by direct product-for-product overlap and more by the varied approaches to solving the same underlying clinical problem.

The company's primary target is the monitoring of arteriovenous fistulas (AVFs) for hemodialysis patients, a critical but narrow segment of the broader dialysis and vascular access market. No direct, named competitor building an identical wearable ultrasound patch was identified in the public record. This absence suggests the company's initial positioning is in a white space, but it also means competition must be mapped across adjacent solution categories.

• Incumbent procedural tools. The current standard of care relies on periodic, in-clinic assessments using handheld Doppler ultrasound machines from major imaging companies like GE HealthCare and Philips. These are not monitoring devices but diagnostic tools used during scheduled visits.
• Emerging monitoring technologies. Several companies are developing continuous monitoring solutions for vascular health, though not all are fistula-specific. Companies like Flosonics Medical (wearable Doppler for hemodynamic monitoring) and Bloom Technologies (formerly, wearable for pregnancy and labor monitoring) demonstrate the technical feasibility of wearable ultrasound, but their clinical applications differ.
• Adjacent substitutes. The competitive threat includes any method that reduces the need for frequent fistula monitoring. This could include superior surgical techniques for creating more durable fistulas, drug-coated balloons to treat stenosis, or entirely different renal replacement therapies that obviate the need for a fistula altogether.

Where Auvi Labs has a potential edge today is in its specific focus and academic origins. The company's entire product, Beacon, is engineered for a single, well-defined use case: detecting AVF narrowing. This focus, spun out from university research, may allow for faster iteration and more targeted clinical validation compared to larger firms with broader portfolios. The edge is perishable, however, as it relies on maintaining a lead in miniaturization and algorithm development before a better-capitalized player decides the niche is worth entering.

The company is most exposed on the commercial and regulatory fronts. It lacks the established sales channels and reimbursement expertise of large medtech incumbents. A competitor like Butterfly Network, with its handheld, whole-body ultrasound system and existing FDA clearances, could theoretically develop a fistula-monitoring accessory or software update, leveraging its commercial infrastructure to capture the market rapidly. Auvi's reliance on a hardware-plus-software model also introduces manufacturing and supply chain risks that pure software monitoring solutions might avoid.

The most plausible 18-month competitive scenario hinges on clinical validation and partnership formation. If Auvi Labs can publish compelling pilot data and secure a development partnership with a dialysis provider (like DaVita or Fresenius Medical Care), it becomes an attractive acquisition target for a strategic player seeking to own the point-of-care monitoring layer. In this scenario, a "winner" could be a smaller, agile diagnostic company looking to expand its renal portfolio. Conversely, if validation is delayed and a competitor like Sonavi Labs (focused on digital auscultation) or a large incumbent releases a competing wearable, Auvi Labs becomes a "loser" in the race for early market adoption, potentially confined to a niche academic project.

PUBLIC The prize for Auvi Labs is a dominant position in the multi-billion dollar, high-stakes market for vascular access surveillance, a critical but historically reactive component of dialysis care.

The headline opportunity is to become the standard-of-care monitoring tool for the roughly 400,000 hemodialysis patients in the United States who rely on arteriovenous fistulas (AVFs) [Illinois Medicine, 2024]. The company's Beacon device aims to shift the paradigm from intermittent, clinic-based ultrasounds to continuous, patient-administered monitoring. If the technology proves accurate and gains regulatory and clinical acceptance, Auvi Labs could embed itself as a recurring-revenue, consumable-driven business within the dialysis treatment pathway, a setting with established reimbursement mechanisms and a captive patient population. The evidence making this outcome reachable, rather than purely aspirational, is the clear articulation of the clinical need and the early validation through a university-affiliated startup competition, which signals foundational technical merit [Illinois Medicine, 2024].

Growth scenarios beyond initial adoption point to significant scale. The most plausible paths are not just about selling more devices, but about expanding the utility of the data platform.

Scenario	What happens	Catalyst	Why it's plausible
Integrated Provider Partnership	Beacon becomes the preferred monitoring tool for a major dialysis provider (e.g., DaVita, Fresenius) and is rolled out across their network.	A successful pilot study demonstrating Beacon's ability to reduce hospitalizations and access failure rates.	Dialysis providers are highly concentrated and have strong incentives to reduce costly complications; they routinely evaluate new technologies for cost-saving and care improvement [Crunchbase].
Data-Driven Predictive Platform	Auvi Labs evolves from a detection device to a predictive analytics platform, selling risk scores and intervention recommendations to payors and health systems.	Accumulation of a proprietary longitudinal dataset from early clinical deployments.	The core product generates unique, time-series physiological data; the company's stated focus on "early detection" logically extends to prediction [Auvi Labs].
Indication Expansion	The underlying wearable ultrasound technology is adapted to monitor other vascular conditions, such as peripheral artery disease (PAD) or deep vein thrombosis (DVT) risk.	FDA clearance for the initial dialysis indication, establishing a regulatory and technical foundation.	The sensor's fundamental function,non-invasive acoustic monitoring of blood flow,is applicable to multiple vascular pathologies, representing a platform opportunity.

What compounding looks like for Auvi Labs is a classic data network effect in a clinical setting. Each deployed device generates patient-specific acoustic profiles and outcomes data. As this dataset grows, the algorithms for detecting and predicting stenosis become more accurate and potentially more personalized. This improved accuracy, in turn, drives better clinical outcomes, which strengthens the case for broader adoption and higher reimbursement rates. That adoption feeds more data back into the system, creating a virtuous cycle. The flywheel's first turn is contingent on initial clinical deployments, for which public evidence is not yet available.

The size of the win can be framed by looking at comparable medical device companies that achieved standard-of-care status in a niche procedural market. For example, iRhythm Technologies, which developed a wearable cardiac monitor, reached a market capitalization of several billion dollars by securing widespread reimbursement and becoming a default diagnostic tool. While iRhythm operates in cardiology, it demonstrates the valuation potential for a successful, single-purpose wearable medical device with recurring revenue. If the "Integrated Provider Partnership" scenario plays out and Auvi Labs captures a substantial portion of the U.S. dialysis patient population, the company could approach a similar scale of enterprise value, anchored by predictable, high-margin consumable sales. This is a scenario-based illustration, not a forecast.

Data Accuracy: YELLOW -- Core opportunity premise is well-sourced from company and clinical literature; growth scenarios are logical extrapolations from the product's stated function but lack specific, corroborated commercial milestones.

Sources

PUBLIC

1. [Auvi Labs] Auvi Labs , Wearable Ultrasound for Vascular Access Monitoring | https://www.auvilabs.com/

2. [Illinois Medicine, 2024] Solution to Improve Dialysis Patient Care Earns CI MED Start-up Winning Investment | https://medicine.illinois.edu/news/solution-to-improve-dialysis-patient-care-earns-ci-med-start-up-winning-investment

3. [YouTube] How Auvi Labs is Building a Wearable Ultrasound Device | https://www.youtube.com/watch?v=fDuFXmx-7DY

4. [SignalBase] Auvi Labs Raises $101K Seed Funding to Advance Dialysis Access Monitoring | https://www.trysignalbase.com/news/funding/auvi-labs-raises-101k-seed-funding-to-advance-dialysis-access-monitoring

5. [PitchBook] Auvi Labs 2025 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/688646-26

6. [Crunchbase] Auvi Labs - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/auvi-labs

7. [Prospeo] Prospeo company listing for Auvi Labs | https://prospeo.io/c/auvi-labs-email-format

8. [Delta: HealthTech Innovators] Delta: HealthTech Innovators - Podcast | https://podcasts.apple.com/ca/podcast/delta-healthtech-innovators/id1703827145

9. [LinkedIn, 2026] Paul Magelli - Greater Chicago Area | Professional Profile | LinkedIn | https://www.linkedin.com/in/paulmagelli/

10. [BBB] BBB profile for Auvi Labs | https://www.bbb.org/us/il/chicago/profile/dialysis-clinic/auvi-labs-0654-1000139723